For the treatment of herpetic eye diseases


(57) Abstract:

The invention can be used in ophthalmology for the treatment of herpetic eye infections, in particular herpes keratitis. The product contains 0.1 g of acyclovir and 10 ml of lacritin. This ratio is known in ophthalmology drugs increases the effectiveness of the treatment, reducing treatment time and lower consumption of medicines.

The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of herpetic eye infections, in particular herpes keratitis.

Known analogues of antiviral drugs - cerezal (idoxuridine) and interferon - have certain disadvantages. Cerezal is used for surface forms of herpetic keratitis, does not penetrate the cornea, toxic, causes dryness of the cornea, ulceration, mitropanos, the obliteration of lacrimal points, cicatricial conjunctivitis with long-term use. Interferon is also used often in insufficient concentration, and in severe deep herpetic eye lesions must apply in parallel with the instillation as subconjunctival injection, and phonophoresis. Also both protover their disadvantage.

In the drug Acyclovir" adopted for the prototype combines high selective activity and minimal toxicity. In numerous comparative studies with instillation in the conjunctival cavity Acyclovir had a therapeutic effect on corneal epithelial lesions caused by keratitis. However, when the local application of the drug was ineffective for the treatment of stromal keratitis, not accompanied by ulceration of the cornea.

The technical result of the invention consists in the improved treatment of herpetic eye diseases, and lower consumption of medicines and the reduction of treatment time.

Technical result is achieved by treatment for herpetic eye diseases on the basis of the active substance is aciclovir with additional content of laricina when following a weight ratio of components: acyclovir 0.1 g, lakrisin 10 mg.

Lakrisin in ophthalmology is used as eye drops for conditions requiring the creation of a protection film on the cornea; diseases, when it is necessary to promote epithelialization of the cornea or which require replacement treatment with reduced secretion of shotonline of the drug in 10 ml of laricina add 0.1 g of dry matter of acyclovir, mix thoroughly before formation of a 1% emulsion of white.

Example 1. Patient D. (history N 495) was treated with a diagnosis of Tree herpetic keratitis in the right eye with ulceration. Before admission to the hospital was sick for 1 month. When admitted to hospital, the condition of the right eye following: narrowed palpebral mixed vascular injection of the conjunctiva of the eyeball. In the paracentral area of the cornea - tree infiltration, increased the fluorescein. Iris is calm, the pupil "sluggish" reacts to light. Globeasia environment is not changed. Visual acuity at admission 0,6/0,8 no Corr. Used 1% for treatment 2 times a day by intellasia in the conjunctival cavity. On the 4th day observed decrease blepharospasm, photophobia, watery eyes, feeling of a foreign body for the ages, a mixed injection of the vessels of the conjunctiva of the eyeball, guardianship of the cornea. The patient was discharged on the 7th day, visual acuity 0,9-1,0/0,9.

Example 2. Patient S. (history N 618) was treated in the hospital of the Institute with a diagnosis of OD - herpetic stromal keratitis with ulceration, keratouveitis. The state of the right eye at the time of hospitalization: blepharospasm, lacrimation, tion zone of the corneal stromal infiltrate with ulceration in the center of it, colored fluorescein, Disamatic. On the endothelium of the cornea in the lower sector of small grayish precipitates. The pupil is expanded by mediatique. The fundus of the eye in the fog without features.

The application of 1% funds for the treatment of stromal infiltration of the cornea has acquired the shape of a disk, salpetersaure, smoothed out the folds of descemetocele shell. The pupil is expanded by mediatique absorbed homogeneous suspension in the vitreous body. When you extract the right eye calm, discoid corneal infiltrate in the reverse phase of development. The pupil is wide, dispersed, suspended in the vitreous body. The fundus of the eye is not changed.

Example 3. When comparing the treatment of patients with ophthalmic herpes in 2 groups of patients treated with 1% medium (1st group) and 3% ointment acyclovir (2nd group), it was found that the average number of hospital days, respectively, and 13,0 18,5, i.e. the treatment of patients offered us 1% of the tool significantly reduces the number of hospital days and accelerates the relief process.

In the treatment of herpetic tree keratitis 1% by means of treatment compared with the treatment of the same form of herpetic keratitis 3% ointment acyclovir duration of treatment was shorter than 9 days (respectively 7 and 18 bed-bottoms the key, compared to the 4-5 th in the treatment with 3% ointment acyclovir.

Thus, the proposed means of speeding epithelialization defects of the cornea, which leads to reduction of treatment time on 5-9 days, in addition, significantly reduced the consumption of the active substance is aciclovir.

For the treatment of herpetic eye diseases based on the active ingredients of acyclovir, wherein the tool further comprises lakrisin, in the following ratio of components: acyclovir 0.1 g lakrisin - 10 ml


Same patents:
The invention relates to medicine, namely to urology and applies to mixed infections of the urinary tract, which is the subject of study of a wide range of scientists, as in the etiopathogenesis of these diseases play an important role as viral and bacterial infections, and the state of cellular and humoral immunity of the drug and treatment urethrovesical infections and herpes

The invention relates to derivatives of benzimidazole and their use in therapy, in particular for the treatment or prophylaxis of viral infections such as caused by herpes viruses

The invention relates to an external preparation for topical application, in particular to the outer local drug use, containing as activitiesthese substance 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or its pharmaceutically acceptable acid salt additive

The invention relates to the medical industry and relates to a composition for the manufacture of containers for infusion solutions
The invention relates to medicine, more specifically to surgery

The invention relates to medicine, in particular to surgery, and may find wide use in practice, treatment of long-term healing of wounds and ulcers, accompanied by the emergence of eczematous contact dermatitis

The invention relates to the field of medicine and for the application of polymer alkylarylsulfonates for effective inhibition of oxidant in chemical or biological system, as well as medications, including those polymeric compounds
The invention relates to pharmaceutical industry and relates to injection or infusion solution of enrofloxacin
The invention relates to the field of medicine and for the treatment of diseases of musculoskeletal system: osteochondrosis, radiculitis, radiculoneuritis, arthritis, arthrosis

The invention relates to novel acyl derivatives of guanosine formula I, inosine formula II, xanthosine formula III, deoxyinosine formula IV, deoxyguanosine formula V, inosine - 2',3'-(acyclic)dialcohol formula VI or pharmaceutically acceptable salts

The invention relates to medicine and can be used for selective destruction of cells infected with RNA of hepatitis C virus(HCV)

The invention relates to medicine

The invention relates to medicine

The invention relates to medicine, in particular, venereology, and for the treatment of chronic trichomoniasis